Lucid has earned a pair of accolades at the recent PMEA Awards for behavioural change programmes it delivered for pharmaceuticals industry clients.
The agency won the Cello Health Award for Launch Excellence for work on behalf of Genzyme and its multiple sclerosis treatment Lemtrada, with the programme using brand advocates and clinical experience to drive dissemination of its core message.
“Lucid's behavioural change programmes for AbbVie and Genzyme have earned prizes at the recent PMEA Awards.“
Additionally, the firm claimed a win in the Excellence in Physicians/Healthcare Provider Support Programmes category for its support for AbbVie's PEER: Psoriasis Expert Exchange FoRum project.
A long-term global programme to improve standards of care in psoriatic disease, the scheme focused on mapping clinical barriers to change and working to address them. The award was presented in recognition of the four-year initiative's first phase.
Fleur Moseley, Lucid's programme director, said: "Measurement of actual clinical practice was integrated throughout the programme, so we can truly say we have advanced clinical practice on a global scale as a result of PEER."
This comes after Lucid won the medical education consultancy of the year prize at the Communique Awards for the third year in succession earlier this year.See all the latest jobs in Healthcare Communications